Search
Fellowships & Grants Committee
Current committee members
Dominique Bonnet, United Kingdom (Chair (EHA Board))
David Kent, United Kingdom (Vice-Chair (non-Board))
Regular members
Renée Beekman, Spain
Olivier Bernard, France
Niccolò Bolli, Italy
Tom Cupedo, The Netherlands
Michaela Fontenay, France
Julia Hauer, Germany
Antonis Kattamis, Greece
Elisa Laurenti, United Kingdom
Dimitrios Mougiakakos, Germany
César Nombela-Arrieta, Switzerland
Rebekka Schneider-Kramann, The Netherlands
Jürg…
EHA Diagnosis
EHA Diagnosis is a new digital tool that EHA has created exclusively for our members.
Read moreFaculty information
We are honored that you have agreed to be part of the faculty for the Highlights of Past EHA (HOPE) MENA 2023, to be held on November 4, 2023 in Antalya, Türkiye.
Read moreFaculty information
We are honored that you have agreed to be part of the faculty for the Highlights of Past EHA (HOPE) Latin America (LA) 2023, to be held on October 26, 2023 in São Paulo, Brazil.
Read moreFaculty Information
We are honored that you have agreed to be a part of the faculty for the EHA-TSH Hematology Tutorial on T Cell Lymphomas, scheduled to be held on June 29-30, 2024 in Ankara, Türkiye.
Read moreAbstract Presentation Information
Thank you for submitting your abstract to the EHA Research Conference 2025, to be held on March 17-20, 2025 in Málaga, Spain.
Read moreSponsor and Fundraising Committee
Current committee members
Martin Dreyling, Germany (Chair (EHA Board))
Antonio Pierini, Italy (Vice Chair (non-Board member))
Igor Aurer, Croatia (Representative, SWG Committee)
Mariane de Montalembert, France (Councilor)
Konstanze Döhner, Germany (EHA Board)
Kirsten Gronbaek, Denmark (EHA Board)
Frank Leebeek, The Netherlands (Councilor)
David Rees, United Kingdom (Representative, Education…
T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy
This press release is originally found here: http://prn. to/2YF7Js3
THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- »